SavedAdd your journal

Journals / İzmir Tepecik Eğitim Hastanesi Dergisi / 2012 / Cilt: 22 - Sayı: 3

Tuberculous pneumonıa related to adalımumabtreatment

Adalimumab kullanımı ile ilişkili tüberküloz pnömonisi

Nimet DEMİRTAŞ
Emel CEYLAN
Fisun KARADAĞ
Mehmet POLATLI
Orhan İLDAĞ
Pages
187–190
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

This case report points out to the fact that protocol starting tuberculosis prophilaxis a few month before anti TNF-alpha treatment should be considered.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:A 54 year-old female patient with a history of rheumatoid arthritis is presented in this article.
📊
Key Findings & Data:She developed pulmonary tuberculosis after 4 months of mistakenly high dose anti TNF-alpha treatment with concomitant 300mg/d Isoniazid prophy- laxis.
💡
Conclusion & Impact:This case report points out to the fact that protocol starting tuberculosis prophilaxis a few month before anti TNF-alpha treatment should be considered.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

A 54 year-old female patient with a history of rheumatoid arthritis is presented in this article. She developed pulmonary tuberculosis after 4 months of mistakenly high dose anti TNF-alpha treatment with concomitant 300mg/d Isoniazid prophy- laxis. This case report points out to the fact that protocol starting tuberculosis prophilaxis a few month before anti TNF-alpha treatment should be considered.

Özet

Bu yazıda, romatoid artrit nedeniyle yüksek dozda Adalimumab tedavisi verilen 54 yaşındaki kadında,eşzamanlı olarak tüberküloz koruyucu tedavi başlanmış olmasına rağmen tedavinin 4.ncü ayında akciğer tüberkülozu gelişen bir olgu sunul- muştur. Bu olgu, TNF-alfa baskılayıcı ilaçları kullanan hastalarda tüberküloz profilaksisine 1-2 ay önce başlayan protokolle- rin daha doğru olduğunu düşündürmektedir.

🔖

Cite This Article

DEMİRTAŞ, N., CEYLAN, E., KARADAĞ, F., POLATLI, M., İLDAĞ, O. (2012). Tuberculous pneumonıa related to adalımumabtreatment. İzmir Tepecik Eğitim Hastanesi Dergisi, Cilt: 22 - Sayı: 3, 187–190. https://ajindex.com/articles/268413

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (5)

  1. Kvien TK, Heiberq, Lie E, Kaufman C, Mikkelsen K, Nordvog BY, Rodevand E. A Norvegian DMARD register: prescriptions of DMARD sand biological agents to patients with inflammatory rheumatic diseases. Clin Exp Rheumatol 2005;23:188-94
  2. Goekoop-Ruiterman YP, de Vries-Bouwstra JK, Allaart CF, Van Zeben D, Kerstens PJ, Hazes JM et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (theBeStstudy): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90
  3. Keane J, Gershon S, Wise RP, Mirabile-Levens E, Kasznica J, Schwieterman WD, et al. Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent. N Engl J Med 2001;345:1098-104
  4. Stenger S, Modlin RL. Control of Mycobacterium tuberculosis through mammalianToll-like receptors. Curr Opin Immunol 2002;14:452-7
  5. Doğan C, Kıral N, Cömert SŞ, Fidan A, Çağlayan B, Salepçi B. Anti TNF- alfa kullanan hastalarda tüberküloz sıklığı. Turk Toraks Derg 2012; 13: 93-98 6. Mutlu GM, Mutlu EA, Bellmeyer A, Rubinstein I. Pulmonary adverse events of anti-tumor necrosis factor-alpha antibody therapy. Am J Med 2006;119:639-46. 7 Braun J, Davis J, Dougados M, Sieper J, Vander Linden S, Van der Heijde D. First update of the international ASAS consensus statement for the use of anti-TNF agents in patients with ankylosing spondylitis. Ann Rheum Dis 2006;65:316-20. 8 Ehlers S. Why does tumor necrosis factor targeted therapy reactivate tuberculosis? J Rheumatol Suppl 2005;74:35-9. 9 Hanta I, Ozbek S, Kuleci S, Kocabas A. The evaluation of latent tuberculosis in rheumatologic diseases for anti TNF Therapy: with 192 patients. Clin Rheumatol 2008;27:1083-6. 10 Askling J, Fored CM, Brandt L, Baecklund E, Bertilsson L, Cöster L, et al. Risk and case characteristics of tuberculosis in rheumatoid arthritis associated with tumor necrosis factor antagonists in Sweden. Arthritis Rheum 2005;52:1986-92. 11 Seong SS, Choi CB, Woo JH, Bae KW, Joung CL, Uhm WS et al. Incidence of tuberculosis in Korean patients with rheumatoid arthritis (RA): effects of RA itself and of tumor necrosis factor blockers. J Rheumatol 2007;34:706-11 12 Özkara Ş, Aktaş Z, Özkan S, Ecevit H. Turkiye’de Tuberkulozun Kontrolu İcin Başvuru Kitabı. Ankara: Sağlık Ba- kanlığı VeremSavaşı Daire Başkanlığı, 2003: 55-7. 13 Keser G, Direskeneli H, Akkoç M, et al. II. RAED Uzlaşı Toplantısı Raporu. 7 Mayıs 2005, İzmir. 14 Centers for Disease Control and Prevention. Tub